Volume | 220,961 |
|
|||||
News | - | ||||||
Day High | 1.382 | Low High |
|||||
Day Low | 1.31 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Personalis Inc | PSNL | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
1.36 | 1.31 | 1.382 | 1.36 | 1.36 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
1,160 | 220,961 | US$ 1.35 | US$ 298,478 | - | 0.8906 - 2.43 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:40:00 | 5 | US$ 1.38 | USD |
Personalis Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
68.69M | 50.50M | - | 73.48M | -108.3M | -2.14 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Personalis News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PSNL Price Data
Period †| Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.35 | 1.42 | 1.2605 | 1.34 | 184,385 | -0.0297 | -2.20% |
1 Month | 1.36 | 1.67 | 1.26 | 1.41 | 207,944 | -0.0397 | -2.92% |
3 Months | 1.48 | 1.85 | 1.18 | 1.42 | 223,190 | -0.1597 | -10.79% |
6 Months | 1.44 | 2.38 | 1.12 | 1.58 | 369,123 | -0.1197 | -8.31% |
1 Year | 2.32 | 2.43 | 0.8906 | 1.51 | 352,634 | -0.9997 | -43.09% |
3 Years | 23.48 | 28.47 | 0.8906 | 6.52 | 422,654 | -22.16 | -94.38% |
5 Years | 23.70 | 53.46 | 0.8906 | 14.51 | 484,210 | -22.38 | -94.43% |
Personalis Description
Personalis Inc is a provider of advanced genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Liquid Biopsy, NeXT Dx Test, and other Pharma Research Solutions. |